50 results on '"Stahel, Rolf A."'
Search Results
2. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
3. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
4. Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment
5. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
6. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
7. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
8. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
9. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
10. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
11. Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial
12. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
13. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
14. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
15. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
16. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
17. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience
18. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
19. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery
20. Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters
21. PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy
22. Inhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells
23. Multimodality Strategies in Malignant Pleural Mesothelioma
24. Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
25. Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer
26. p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
27. Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
28. Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages
29. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
30. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
31. The Cytochrome b5 Tail Anchors and Stabilizes Subdomains of Human DNA Topoisomerase IIα in the Cytoplasm of Retrovirally Infected Mammalian Cells
32. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
33. PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09)
34. P3.03-044 Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?: Topic: Mesothelioma Clinical
35. P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project: Topic: Driver Genes in NSCLC, Resistance, and Other
36. Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (
37. Human Leukocyte Antigen G Up-Regulation in Lung Cancer Associates with High-Grade Histology, Human Leukocyte Antigen Class I Loss and Interleukin-10 Production
38. T1151 Chimeric Recombinant Anti-CD24 Antibody: A Novel Tool for Colorectal Cancer Therapy
39. PD2-3-1: Prognostic significance and origin of plasma KRAS mutations in patients with non-small cell lung cancer (NSCLC)
40. D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC
41. C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP)
42. C3-07: Preoperative chemoradiotherapy followed by surgery for stage IIIB non-small cell lung cancer (NSCLC). A multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
43. Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.
44. Welcome to the 3rd European Lung Cancer Conference
45. Small cell lung cancer: The new biology
46. Chromosome changes in malignant mesothelioma
47. Monoclonal Antibodies in Lung Cancer
48. Fate of Contaminating t(14;18)+ Lymphoma Cells During Ex Vivo Expansion of CD34-Selected Hematopoietic Progenitor Cells
49. CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells
50. Association of CD24 with the Kinase c-fgr in a Small Cell Lung Cancer Cell Line and with the Kinase lyn in an Erythroleukemia Cell Line
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.